This review underscores key emerging concepts, such as the pathophysiological relevance of IPF, the interface between obesity and immunometabolism in pancreatic pathology, and the therapeutic potential of modern weight loss agents, including GLP-1 receptor agonists and dual incretin therapies. This evidence concerns the gene GCG and obesity disorder.